DE3750906T2 - Chemisch modifizierte Proteine und deren Herstellung. - Google Patents

Chemisch modifizierte Proteine und deren Herstellung.

Info

Publication number
DE3750906T2
DE3750906T2 DE3750906T DE3750906T DE3750906T2 DE 3750906 T2 DE3750906 T2 DE 3750906T2 DE 3750906 T DE3750906 T DE 3750906T DE 3750906 T DE3750906 T DE 3750906T DE 3750906 T2 DE3750906 T2 DE 3750906T2
Authority
DE
Germany
Prior art keywords
chemically modified
modified proteins
group
production
imidoester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3750906T
Other languages
English (en)
Other versions
DE3750906D1 (de
Inventor
Hayao Ueno
Masahiko Fujino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE3750906D1 publication Critical patent/DE3750906D1/de
Publication of DE3750906T2 publication Critical patent/DE3750906T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE3750906T 1986-03-10 1987-03-06 Chemisch modifizierte Proteine und deren Herstellung. Expired - Fee Related DE3750906T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5306186 1986-03-10

Publications (2)

Publication Number Publication Date
DE3750906D1 DE3750906D1 (de) 1995-02-09
DE3750906T2 true DE3750906T2 (de) 1995-06-29

Family

ID=12932327

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3750906T Expired - Fee Related DE3750906T2 (de) 1986-03-10 1987-03-06 Chemisch modifizierte Proteine und deren Herstellung.

Country Status (8)

Country Link
US (1) US5109120A (de)
EP (1) EP0236987B1 (de)
JP (1) JP2514950B2 (de)
AT (1) ATE116338T1 (de)
CA (1) CA1336967C (de)
DE (1) DE3750906T2 (de)
ES (1) ES2065880T3 (de)
GR (1) GR3015558T3 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5681720A (en) * 1986-12-23 1997-10-28 Kyowa Hakko Co., Ltd. DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO1991008229A1 (de) * 1989-12-01 1991-06-13 Basf Aktiengesellschaft Hirudinpolyalkylenglykolkonjugate
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
DE69128944T2 (de) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1993012142A1 (en) * 1991-12-10 1993-06-24 Tanox Biosystems, Inc. Cytokines with an unpaired cysteine residue and conjugates thereof
WO1993013131A1 (en) * 1991-12-24 1993-07-08 Sumitomo Seika Chemicals Co., Ltd. Process for producing protein-synthetic polymer composite and said composite produced thereby
US5414135A (en) * 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
TW263437B (de) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
NZ276943A (en) * 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1997016204A1 (en) 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
ES2172288T3 (es) 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
CZ300762B6 (cs) * 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
CO5170404A1 (es) 1999-04-08 2002-06-27 Schering Corp Terapia para melanomas
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CA2390292A1 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
HUE028163T2 (en) 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
US7524931B2 (en) 2002-07-03 2009-04-28 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20090214472A1 (en) * 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
EP1893211B1 (de) 2005-06-17 2011-09-14 Novartis AG Verwendung von sanglifehrin bei der hcv-therapie
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
GB2438834A (en) * 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
MX2013003903A (es) 2010-10-05 2013-05-20 Novartis Ag Nuevos tratamientos de infeccion por el virus de hepatitis c.
WO2012048235A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
AU2011334984A1 (en) 2010-11-30 2013-07-04 Novartis Ag New treatments of Hepatitis C virus infection
CN103476409A (zh) 2011-03-31 2013-12-25 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
WO2012131061A1 (en) 2011-04-01 2012-10-04 Novartis Ag Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
CA2850052A1 (en) 2011-09-27 2013-04-04 Novartis Ag Alisporivr for treatment of hepatis c virus infection
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3782652A1 (de) 2014-08-19 2021-02-24 Biogen MA Inc. Pegylierungsverfahren
AU2016349685A1 (en) 2015-11-03 2018-03-15 F. Hoffmann-La Roche Ag Combination therapy of an HBV capsid assembly inhibitor and an interferon
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146472A (en) * 1913-10-20 1921-10-05 Standard Oil Company Of New Yo Improvements in obtaining products from petroleum by decomposition of component hydrocarbons thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4460560A (en) * 1982-06-18 1984-07-17 University Of Southern California Drug delivery by polymeric carriers
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
EP0154316B1 (de) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CA1336967C (en) 1995-09-12
EP0236987A2 (de) 1987-09-16
JPS6310800A (ja) 1988-01-18
US5109120A (en) 1992-04-28
ATE116338T1 (de) 1995-01-15
DE3750906D1 (de) 1995-02-09
ES2065880T3 (es) 1995-03-01
GR3015558T3 (en) 1995-06-30
EP0236987A3 (en) 1990-05-30
EP0236987B1 (de) 1994-12-28
JP2514950B2 (ja) 1996-07-10

Similar Documents

Publication Publication Date Title
DE3750906T2 (de) Chemisch modifizierte Proteine und deren Herstellung.
FI901530A0 (fi) Menetelmä immunomoduloivien atsaspiraanien valmistamiseksi
DE3483869D1 (de) Zusammensetzungen zur bekaempfung von toxaemia.
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
DK0779291T3 (da) Med heterocyclylcarbonyl substituerede benzofuranyl-urinstoffer
EA199800768A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
ATE36859T1 (de) 4'-demethyl-4-epipodophyllotoxin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE69226815T2 (de) 1-Methyl-carbapenemderivate, deren Herstellung und Verwendung als Antibiotika
ES543153A0 (es) Metodo de preparar derivados de b-carbolin-3-oxadiazolilo
DE3776391D1 (de) Fluessige zubereitungen von 1,2-benzisothiazolin-3-on, ihre herstellung und verwendung.
DK0392560T3 (da) Diaminoethylenforbindelser
DE59509910D1 (de) Verfahren zur Herstellung von Alkylhydrogenchlorsilanen
DE3876536D1 (de) Oxadiazol-pyrimidinone, ihre herstellung und ihre kosmetische und dermopharmazeutische verwendung.
ATE45746T1 (de) Substituierte o-acyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung.
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
ES2059595T3 (es) Beta-carbonil-carboxiamidas de 1,3-tiazolidinas.
ATE97404T1 (de) Prostazyklin-(pgi2)-analoge.
EP0289804A3 (de) Verfahren zur Herstellung von optisch aktiven Mercapto-Verbindungen
ATE43342T1 (de) Verfahren zur herstellung von hydrogeno- oder halogenosilanen.
DE3673129D1 (de) Alkylcarbonsaeureamide von pyridinalkylaminen, ihre herstellung und ihre verwendung als arzneimittel.
KR850007247A (ko) 바이페닐릴설포닐 우레아의 제조방법
BR8600034A (pt) Composto de eter de fenila e processo de preparacao
ATE128963T1 (de) Amine mit fungizider wirkung.
DE69407042D1 (de) Psoralen-derivate, deren herstellung und verwendung als arzneimittel
KR880007502A (ko) 신규의 아미노알카노일-디벤조[d, g][1,3,6]디옥사조신 및 그의 제조방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee